Targeting Human Immunodeficiency Virus Type 1 Assembly, Maturation and Budding

The targets for licensed drugs used for the treatment of human immunodeficiency virus type 1 (HIV-1) are confined to the viral reverse transcriptase (RT), protease (PR), and the gp41 transmembrane protein (TM). While currently approved drugs are effective in controlling HIV-1 infections, new drug ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wapling, Johanna, Srivastava, Seema, Shehu-Xhilaga, Miranda, Tachedjian, Gilda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155237/
https://www.ncbi.nlm.nih.gov/pubmed/21901072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155237/
https://www.ncbi.nlm.nih.gov/pubmed/21901072

Ejemplares similares